Extracellular proteases as targets for drug development

Current Protein and Peptide Science

Volumn 10, Issue 4, 2009, Pages 297-307

  Cudic, Mare ^a   Fields, Gregg B ^b  

^a FLORIDA ATLANTIC UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Cysteine proteases; Drug targets; Extracellular proteases; Metalloproteases; Protease inhibitors; Serine proteases

Indexed keywords

ADAM PROTEIN; ARGATROBAN; BLOOD CLOTTING FACTOR; CYSTEINE PROTEINASE; DESULFATOHIRUDIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV; DOXYCYCLINE HYCLATE; ELASTASE; EXTRACELLULAR PROTEASE; FONDAPARINUX; GLUTAMATE CARBOXYPEPTIDASE II; HIRULOG; KALLIKREIN; LEPIRUDIN; MATRIX METALLOPROTEINASE; MEMBRANE METALLOENDOPEPTIDASE; METALLOCARBOXYPEPTIDASE; OMAPATRILAT; PEPTIDE HYDROLASE; PREGNANCY ASSOCIATED PLASMA PROTEIN A; PROTEINASE; SERINE PROTEINASE; SITAGLIPTIN; TISSUE PLASMINOGEN ACTIVATOR; TRYPTASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE; XIMELAGATRAN;

ANGIONEUROTIC EDEMA; ANTICOAGULATION; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HYPERTENSION; NONHUMAN; PROTEIN TARGETING; REVIEW; VENOUS THROMBOEMBOLISM;

ANIMALS; DRUG DISCOVERY; EXTRACELLULAR SPACE; HUMANS; PEPTIDE HYDROLASES; PROTEASE INHIBITORS;

EID: 70349506754     PISSN: 13892037     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920309788922207     Document Type: Review

References (147)

1. Ashton, P. D.; Curwen, R. S.; Wilson, R. A. Linking proteome and genome: how to identify parasite proteins. Trends Parasitol., 2001, 17, 198-202.
2. Weng, Z.; DeLisi, C. Protein therapeutics: promises and challenges for the 21st century. Trends Biotechnol., 2002, 20, 29-35.
3. Turk, B. Targeting proteases: successes, failures and future prospects. Nat. Rev. Drug Discov., 2006, 5, 785-799.
4. Abberiante, G.; Fairlie, D.P. Protease inhibitors in the clinic. Med. Chem., 2005, 1, 71-104.
5. Overall, C. M.; Blobel, C. P. In search of partners: linking extracellular proteases to substrates. Nat. Rev. Mol. Cell Biol., 2007, 8, 245-257.
6. Fields, G. B. In Protease-activated delivery and imaging system. Edwards, D.; Hoyer-Hansen, G.; Blasi, F.; Sloane, B., Eds.; Springer: New York, 2009, in press.
7. Woessner, J. F., Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J., 1991, 5, 2145-2154.
8. Page-McCaw, A.; Ewald, A. J.; Werb, Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol., 2007, 8, 221-233.
9. Chang, C.;. Werb, Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol., 2001, 11, S37-43.
10. Egeblad, M.; Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer, 2002, 2, 161-174.
11. Ishiguro, N.; Ito, T.; Oguchi, T.; Kojima, T.; Iwata, H.; Ionescu, M.; Poole, A. R. Relationships of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover and inflammation as revealed by analyses of synovial fluids from patients with rheumatoid arthritis. Arthritis Rheum., 2001, 44, 2503-2511.
12. Skiles, J. W.; Gonnella, N. C.; Jeng, A. Y. The design, structure, and therapeutic application of matrix metalloproteinase inhibitors. Curr. Med. Chem., 2001, 8, 425-474.
13. Verma, R. P.; Hansch, C. Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs. Bioorg. Med. Chem., 2007, 15, 2223-2268.
14. Lauer-Fields, J.; Brew, K.; Whitehead, J. K.; Li, S.; Hammer, R. P.; Fields, G.B. Triple-helical transition state analogues: a new class of selective matrix metalloproteinase inhibitors. J. Am. Chem. Soc., 2007, 129, 10408-10417.
15. Sawa, M.; Kiyoi, T.; Kurokawa, K.; Kurnihara, H.; Yamamoto, M.; Miyasaka, T.; Ito, Y.; Hirayama, R.; Inoue, T.; Kirii, Y.; Nishiwaki, E.; Ohmoto, H.; Maeda, Y.; Ishibushi, E.; Inoue, Y.; Yoshino, K.; Kondo, H. New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids. J. Med. Chem., 2002, 45, 919-929.
16. Lauer-Fields, J.L.; Whitehead, J.K.; Li, S.; Hammer, R.P.; Brew, K. and Fields, G.B. Selective modulation of matrix metalloproteinase 9 (MMP-9) functions via exosite inhibition. J. Biol. Chem., 2008, 283, 20087-20095.
17. Puerta, D. T.; Lewis, J. A.; Cohen, S. M. New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zinc-binding groups. J. Am. Chem. Soc., 2004, 126, 8388-8389.
18. Stocker, W.; Grams, F.; Baumann, U.; Reinemer, P.; Gomis-Ruth, F. X.; McKay, D. B.; Bode, W. The metzincins-topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases. Protein Sci., 1995, 4, 823-840.
19. Porter, S.; Clark, L.M.; Kevorkian, L.; Edwards, D.R. The ADAMTS metalloproteinases. Biochem. J., 2005, 386, 15-27.
20. Blobel, C. P. Functional and biochemical characterization of ADAMs and their predicted role in protein ectodomain shedding. Inflamm. Res., 2002, 51, 83, 84.
21. Bridges, L.C.; Bowditch, R.D. ADAM-Integrin Interactions: potential integrin regulated ectodomain shedding activity. Curr. Pharm. Des., 2005, 11, 837-847.
22. Amour, A.; Knight, C.G.; English, W.R.; Webster, A.; Slocombe, P.M.; Knauper, V.; Docherty, A.J.; Becherer, J.D.; Blobel, C.P.; Murphy, G. The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs. FEBS Lett., 2002, 524, 154-158.
23. Loechel, F.; Fox, J.W.; Murphy, G.; Albrechtsen, R.; Wewer, U.M. ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem. Biophys. Res. Commun., 2000, 278, 511-515.
24. Black, R.A. Tumor necrosis factor-alpha converting enzyme. Int. J. Biochem. Cell Biol., 2002, 34, 1-5.
25. Hidalgo, M.; Eckhardt, S.G. Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl. Cancer Inst., 2001, 93, 178-193.
26. Barlaam, B.; Bird, T.G.; Lambert-Van Der Brempt, C.; Campbell, D.; Foster, S.J.; Maciewicz, R. New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors. J. Med. Chem., 1999, 42, 4890-4908.
27. Reiss, K.; Ludwig, A.; Saftig, P. Breaking up the tie: disintegrin-like metalloproteinases as regulators of cell migration in inflammation and invasion. Pharmacol. Ther., 2006, 111, 985-1006.
28. Jones, G.C. ADAMTS proteinases: potential therapeutic targets? Curr. Pharm. Biotechnol., 2006, 7, 25-31.
29. Kern, C.B.; Twal, W.O.; Mjaatvedt, C.H.; Fairey, S.E.; Toole, B.P.; Iruela-Arispe, M.L.; Argraves, W.S. Proteolytic cleavage of versican during cardiac cushion morphogenesis. Dev. Dyn., 2006, 235, 2238-2247.
30. Manso, A.M.; Elsherif, L.; Kang, S.M.; Ross, R.S. Integrins, membrane-type matrix metalloproteinases and ADAMs: potential implications for cardiac remodeling. Cardiovasc. Res., 2006, 69, 574-584.
31. Rocks, N.; Paulissen, G.; El Hour, M.; Quesada, F.; Crahay, C.; Gueders, M.; Foidart, J.M.; Noel, A.; Cataldo, D. Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie, 2008, 90(2), 369-379.
32. Moss, M.L.; Bartsch, J.W. Therapeutic benefits from targeting of ADAM family members. Biochemistry, 2004, 43, 7227-7235.
33. Levy, G.G.; Nichols, W.C.; Lian, E.C.; Foroud, T.; McClintick, J.N.; McGee, B.M.; Yang, A.Y.; Siemieniak, D.R.; Stark, K.R.; Gruppo, R.; Sarode, R.; Shurin, S.B.; Chandrasekaran, V.; Stabler, S.P.; Sabio, H.; Bouhassira, E.E.; Upshaw, J.D., Jr.; Ginsburg, D.; Tsai, H.M. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature, 2001, 413, 488-494.
34. Van Eerdewegh, P.; Little, R.D.; Dupuis, J.; Del Mastro, R.G.; Falls, K.; Simon, J.; Torrey, D.; Pandit, S.; McKenny, J.; Braunschweiger, K.; Walsh, A.; Liu, Z.; Hayward, B.; Folz, C.; Manning, S.P.; Bawa, A.; Saracino, L.; Thackston, M.; Benchekroun, Y.; Capparell, N.; Wang, M.; Adair, R.; Feng, Y.; Dubois, J.; FitzGerald, M.G.; Huang, H.; Gibson, R.; Allen, K.M.; Pedan, A.; Danzig, M.R.; Umland, S.P.; Egan, R.W.; Cuss, F.M.; Rorke, S.; Clough, J.B.; Holloway, J.W.; Holgate, S.T.; Keith, T.P. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature, 2002, 418, 426-430.
35. Foley, S.C.; Mogas, A.K.; Olivenstein, R.; Fiset, P.O.; Chakir, J.; Bourbeau, J.; Ernst, P.; Lemiere, C.; Martin, J.G.; Hamid, Q. Increased expression of ADAM33 and ADAM8 with disease progression in asthma. J. Allergy Clin. Immunol., 2007, 119, 863-871.
36. King, N.E.; Zimmermann, N.; Pope, S.M.; Fulkerson, P.C.; Nikolaidis, N.M.; Mishra, A.; Witte, D.P.; Rothenberg, M.E. Expression and regulation of a disintegrin and metalloproteinase (ADAM) 8 in experimental asthma. Am. J. Respir. Cell Mol. Biol., 2004, 31, 257-265.
37. Al-Fakhri, N.; Wilhelm, J.; Hahn, M.; Heidt, M.; Hehrlein, F.W.; Endisch, A.M.; Hupp, T.; Cherian, S.M.; Bobryshev, Y.V.; Lord, R.S.; Katz, N. Increased expression of disintegrin-metalloproteinases ADAM-15 and ADAM-9 following upregulation of integrins alpha5beta1 and a1phavbeta3 in atherosclerosis. J. Cell Biochem., 2003, 89, 808-823.
38. East, C.J.; Stanton, H.; Golub, S.B.; Rogerson, F.M.; Fosang, A.J. ADAMTS-5 deficiency does not block aggrecanolysis at preferred cleavage sites in the chondroitin sulfate-rich region of aggrecan. J. Biol. Chem., 2007, 282, 8632-8640.
39. Little, C.B.; Meeker, C.T.; Golub, S.B.; Lawlor, K.E.; Farmer, P.J.; Smith, S.M.; Fosang, A.J. Blocking aggrecanase cleavage in the aggrecan interglobular domain abrogates cartilage erosion and promotes cartilage repair. J. Clin. Invest., 2007, 117, 1627-1636.
40. Stanton, H.; Rogerson, F.M.; East, C.J.; Golub, S.B.; Lawlor, K.E.; Meeker, C.T.; Little, C.B.; Last, K.; Farmer, P.J.; Campbell, I.K.; Fourie, A.M.; Fosang, A.J. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature, 2005, 434, 648-652.
41. Gendron, C.; Kashiwagi, M.; Lim, N.H.; Enghild, J.J.; Thogersen, I.B.; Hughes, C.; Caterson, B.; Nagase, H. Proteolytic activities of human ADAMTS-5: comparative studies with ADAMTS-4. J. Biol. Chem., 2007, 282, 18294-18306.
42. Matthews, R.T.; Gary, S.C.; Zerillo, C.; Pratta, M.; Solomon, K.; Amer, E.C.; Hockfield, S. Brain-enriched hyaluronan binding (BEHAB)/brevican cleavage in a glioma cell line is mediated by a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) family member. J. Biol. Chem., 2000, 275, 22695-22703.
43. Porter, S.; Span, P.N.; Sweep, F.C.; Tjan-Heijnen, V.C.; Pennington, C.J.; Pedersen, T.X.; Johnsen, M.; Lund, L.R.; Romer, J.; Edwards, D.R. ADAMTS8 and ADAMTS15 expression predicts survival in human breast carcinoma. Int. J. Cancer, 2006, 118, 1241-1247.
44. Iba, K.; Albrechtsen, R.; Gilpin, B.J.; Loechel, F.; Wewer, U.M. Cysteine-rich domain of human ADAM 12 (meltrin alpha) supports tumor cell adhesion. Am. J. Pathol., 1999, 154, 1489-1501.
45. Iba, K.; Albrechtsen, R.; Gilpin, B.; Frohlich, C.; Loechel, F.; Zolkiewska, A.; Ishiguro, K.; Kojima, T.; Liu, W.; Langford, J.K.; Sanderson, R.D.; Brakebusch, C.; Fassler, R.; Wewer, U.M. The cysteine-rich domain of human ADAM 12 supports cell adhesion through syndecans and triggers signaling events that lead to beta1 integrin-dependent cell spreading. J. Cell Biol., 2000, 149, 1143-1156.
46. Kashiwagi, M.; Tortorella, M.; Nagase, H.; Brew, K. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J. Biol. Chem., 2001, 276, 12501-12504.
47. Ludwig, A.; Hundhausen, C.; Lambert, M.H.; Broadway, N.; Andrews, R.C.; Bickett, D.M.; Leesnitzer, M.A.; Becherer, J.D. Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules. Comb. Chem. High Throughput Screen, 2005, 8, 161-171.
48. Rao, B.G. Recent developments in the design of specific Matrix Metalloproteinase inhibitors aided by structural and computational studies. Curr. Pharm. Des., 2005, 11, 295-322.
49. Drummond, A.H.; Beckett, P.; Brown, P.D.; Bone, E.A.; Davidson, A.H.; Galloway, W.A.; Gearing, A.J.; Huxley, P.; Laber, D.; McCourt, M.; Whittaker, M.; Wood, L.M.; Wright, A. Preclinical and clinical studies of MMP inhibitors in cancer. Ann. N. Y. Acad Sci., 1999, 878, 228-235.
50. Boldt, H.B.; Overgaard, M.T.; Laursen, L.S.; Weyer, K.; Sottrup-Jensen, L.; Oxvig, C. Mutational analysis of the proteolytic domain of pregnancy-associated plasma protein-A (PAPP-A): classification as a metzincin. Biochem. J., 2001, 358, 359-367.
51. Lawrence, J.B.; Oxvig, C.; Overgaard, M.T.; Sottrup-Jensen, L.; Gleich, G.J.; Hays, L.G.; Yates, J.R., 3rd; Conover, C.A. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc. Natl. Acad. Sci. USA, 1999, 96, 3149-3153.
52. Overgaard, M.T.; Boldt, H.B.; Laursen, L.S.; Sottrup-Jensen, L.; Conover, C.A.; Oxvig, C. Pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth factor-binding protein-5 proteinase. J. Biol. Chem., 2001, 276, 21849-21853.
53. Overgaard, M.T.; Haaning, J.; Boldt, H.B.; Olsen, I.M.; Laursen, L.S.; Christiansen, M.; Gleich, G.J.; Sottrup-Jensen, L.; Conover, C.A.; Oxvig, C. Expression of recombinant human pregnancy-associated plasma protein-A and identification of the proform of eosinophil major basic protein as its physiological inhibitor. J. Biol. Chem., 2000, 275, 31128-31133.
54. Bayes-Genis, A.; Conover, C.A.; Overgaard, M.T.; Bailey, K.R.; Christiansen, M.; Holmes, D.R., Jr.; Virmani, R.; Oxvig, C.; Schwartz, R.S. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N. Engl. J. Med., 2001, 345, 1022-1029.
55. Valentinis, B.; Baserga, R. IGF-I receptor signalling in transformation and differentiation. Mol. Pathol., 2001, 54, 133-137.
56. Rossert, J.; Terraz-Durasnel, C.; Brideau, G. Growth factors, cytokines, and renal fibrosis during the course of diabetic nephropathy. Diabetes Metab., 2000, 26, 16-24.
57. Kerr, M.A.; Kenny, A.J. The purification and specificity of a neutral endopeptidase from rabbit kidney brush border. Biochem. J., 1974, 137, 477-488.
58. Kerr, M.A.; Kenny, A.J. The molecular weight and properties of a neutral metallo-endopeptidase from rabbit kidney brush border. Biochem. J., 1974, 137, 489-495.
59. Roques, B.P.; Fournie-Zaluski, M.C.; Soroca, E.; Lecomte, J.M.; Malfroy, B.; Llorens, C.; Schwartz, J.C. The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice. Nature, 1980, 288, 286-288.
60. Roques, B.P.; Noble, F.; Dauge, V.; Fournie-Zaluski, M.C.; Beaumont, A. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacolugy. Pharmacol. Rev., 1993, 45, 87-146.
61. Shirotani, K.; Tsubuki, S.; Iwata, N.; Takaki, Y.; Harigaya, W.; Maruyama, K.; Kiryu-Seo, S.; Kiyama, H.; Iwata, H.; Tomita, T.; Iwatsubo, T.; Saido, T.C. Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases. J. Biol. Chem., 2001, 276, 21895-21901.
62. Iwata, N.; Tsubuki, S.; Takaki, Y.; Shirotani, K.; Lu, B.; Gerard, N.P.; Gerard, C.; Hama, E.; Lee, H.J.; Saido, T.C. Metabolic regulation of brain Abeta by neprilysin. Science, 2001, 292, 1550-1552.
63. Burnett, J.C.; Jr. Vasopeptidase inhibition: a new concept in blood pressure management. J. Hypertens. Suppl., 1999, 17, S37-43.
64. Roques, B.P.; Beaumont, A. Neutral endopeptidase-24.11 inhibitors: from analgesics to antihypertensives? Trends Pharmacol. Sci., 1990, 11, 245-249.
65. Oefner, C.; Pierau, S.; Schulz, H.; Dale, G.E. Structural studies of a bifunctional inhibitor of neprilysin and DPP-IV. Acta Crystallogr. D Biol. Crystallogr., 2007, 63, 975-981.
66. Zaman, M.A.; Oparil, S.; Calhoun, D.A. Drugs targeting the reninangiotensin-aldosterone system. Nat. Rev. Drug. Discov., 2002, 1, 621-636.
67. Acharya, K.R., Sturrock, E.D.; Riordan, J.F.; Ehlers, M.R. Ace revisited: a new target for structure-based drug design. Nat. Rev. Drug Discov., 2003, 2, 891-902.
68. Natesh, R.; Schwager, S.L.; Sturrock, E.D.; Acharya, K.R. Crystal structure of the human angiotensin-converting enzyme-lisinopril complex. Nature, 2003, 421, (6922), 551-554.
69. Jandeleit-Dahm, K.A. Dual ACE/NEP inhibitors - more than playing the ACE card. J. Hum. Hypertens., 2006, 20, 478-481.
70. Robl, J.A.; Sun, C.Q.; Stevenson, J,; Ryono, D.E.; Simpkins, L.M.; Cimarusti, M.P.; Dejneka, T.; Slusarchyk, W.A.; Chao, S.; Stratton, L.; Misra, R.N.; Bednarz, M.S.; Asaad, M.M.; Cheung, H.S.; Abboa-Offei, B.E.; Smith, P.L.; Mathers, P.D.; Fox, M.; Schaeffer, T.R.; Seymour, A.A.; Trippodo, N.C. Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J. Med. Chem., 1997, 40(11), 1570-1577.
71. Vendrell, J.; Querol, E.; Aviles, F.X. Metallocarboxypeptidases and their protein inhibitors. Structure, function and biomedical properties. Biochim. Biophys. Acta, 2000, 1477, 284-298.
72. Reznik, S.E.; Fricker, L.D. Carboxypeptidases from A to Z: implications in embryonic development and Wnt binding. Cell Mol. Life Sci., 2001, 58, 1790-1804.
73. Wei, S.; Feng, Y.; Kalinina, E.; Fricker, L.D. Neuropeptide-processing carboxypeptidases. Life Sci., 2003, 73, 655-662.
74. Arolas, J.L.; Vendrell, J.; Aviles, F.X.; Fricker, L.D. Metallocarboxypeptidases: emerging drug targets in biomedicine. Curr. Pharm. Des., 2007, 13, 349-366.
75. Bajzar, L.; Manuel, R.; Nesheim, M.E. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J. Biol. Chem., 1995, 270, 14477-14484.
76. Bajzar, L.; Morser, J.; Nesheim, M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J. Biol. Chem., 1996, 271, 16603-16608.
77. Eaton, D.L.; Malloy, B.E.; Tsai, S.P.; Henzel, W.; Drayna, D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J. Biol. Chem., 1991, 266, 21833-21838.
78. Wang, W.; Hendriks, D.F.; Scharpe, S.S. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J. Biol. Chem., 1994, 269, 15937-15944.
79. Wang, W.; Boffa, M.B.; Bajzar, L.; Walker, J.B.; Nesheim, M.E. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J. Biol. Chem., 1998, 273, 27176-27181.
80. Bouma, B.N.; Mosnier, L.O. Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis. Pathophysiol. Haemost. Thromb., 2003, 33, 375-381.
81. Klement, P.; Liao, P.; Bajzar, L. A novel approach to arterial thrombolysis. Blood, 1999, 94, 2735-2743.
82. Nagashima, M.; Werner, M.; Wang, M.; Zhao, L.; Light, D.R.; Pagila, R.; Morser, J.; Verhallen, P. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model. Thromb. Res., 2000, 98, 333-342.
83. Bajzar, L.; Jain, N.; Wang, P.; Walker, J.B. Thrombin activatable fibrinolysis inhibitor: not just an inhibitor of fibrinolysis. Crit. Care Med., 2004, 32, S320-324.
84. Rawlings, N.D.; Barrett, A.J. Structure of membrane glutamate carboxypeptidase. Biochim. Biophys. Acta, 1997, 1339, 247-252.
85. Mesters, J.R.; Barinka, C.; Li, W.; Tsukamoto, T.; Majer, P.; Slusher, B.S.; Konvalinka, J.; Hilgenfeld, R. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J., 2006, 25, 1375-1384.
86. Robinson, M.B.; Blakely, R.D.; Couto, R.; Coyle, J.T. Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. J. Biol. Chem., 1987, 262, 14498-14506.
87. Rojas, C.; Frazier, S.T.; Flanary, J.; Slusher, B.S. Kinetics and inhibition of glutamate carboxypeptidase II using a microplate assay. Anal. Biochem., 2002, 310, 50-54.
88. Zhou, J.; Neale, J.H.; Pomper, M.G.; Kozikowski, A.P. NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat. Rev. Drug Discov., 2005, 4, 1015-1026.
89. Slusher, B.S.; Vornov, J.J.; Thomas, A.G.; Hurn, P.D.; Harukuni, I.; Bhardwaj, A.; Traystman, R.J.; Robinson, M.B.; Britton, P.; Lu, X.C.; Tortella, F.C.; Wozniak, K.M.; Yudkoff, M.; Potter, B.M.; Jackson, P.F. Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat. Med., 1999, 5, 1396-1402.
90. Jackson, P.F.; Slusher, B.S. Design of NAALADase inhibitors: a novel neuroprotective strategy. Curr. Med. Chem., 2001, 8, 949-957.
91. Carter, R.E.; Feldman, A.R.; Coyle, J.T. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc. Natl. Acad. Sci. USA, 1996, 93, 749-753.
92. Tiffany, C.W.; Lapidus, R.G.; Merion, A.; Calvin, D.C.; Slusher, B.S. Characterization of the enzymatic activity of PSM: comparison with brain NAALADase. Prostate, 1999, 39, 28-35.
93. Su, S.L.; Huang, I.P.; Fair, W.R.; Powell, C.T.; Heston, W.D. Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res., 1995, 55, 1441-1443.
94. Pinto, J.T.; Suffoletto, B.P.; Berzin, T.M.; Qiao, C.H.; Lin, S.; Tong, W.P.; May, F.; Mukherjee, B.; Heston, W.D. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin. Cancer Res., 1996, 2, 1445-1451.
95. Heston, W.D. Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase. Urology, 1997, 49, 104-112.
96. Garcia-Touchard, A.; Henry, T.D.; Sangiorgi, G.; Spagnoli, L.G.; Mauriello, A.; Conover, C.; Schwartz, R.S. Extracellular proteases in atherosclerosis and restenosis. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 1119-1127.
97. Ohbayashi, H. Neutrophil elastase inhibitors as treatment for COPD. Expert Opin. Investig. Drugs, 2002, 11, 965-980.
98. Bernstein, P.R.; Edwards, P.D.; Williams, J.C. Inhibitors of human leukocyte elastase. Prog. Med. Chem., 1994, 31, 59-120.
99. Doring, G. The role of neutrophil elastase in chronic inflammation. Am. J. Respir. Crit. Care Med, 1994, 150, S114-117.
100. Harris, M.; Firsov, D.; Vuagniaux, G.; Stutts, M.J.; Rossier, B.C. A novel neutrophil elastase inhibitor prevents elastase activation and surface cleavage of the epithelial sodium channel expressed in Xenopus laevis oocytes. J. Biol. Chem., 2007, 282, 58-64.
101. Steinbrecher, T.; Case, D.A.; Labahn, A. A multistep approach to structure-based drug design: studying ligand binding at the human neutrophil elastase. J. Med. Chem., 2006, 49, 1837-1844.
102. Attucci, S.; Gauthier, A.; Korkmaz, B.; Delepine, P.; Martino, M.F.; Saudubray, F.; Diot P.; Gauthier, F. EPI-hNE4, a proteolysis-resistant inhibitor of human neutrophil elastase and potential anti-inflammatory drug for treating cystic fibrosis. J. Pharmacol. Exp. Ther., 2006, 318, 803-809.
103. Prezelj, A.; Anderluh, P.S.; Peternel, L.; Urleb, U. Recent advances in serine protease inhibitors as anticoagulant agents. Curr. Pharm. Des., 2007, 13, 287-312.
104. Di Nisio, M.; Middeldorp, S.; Buller, H.R. Direct thrombin inhibitors. N. Engl. J. Med., 2005, 353, 1028-1040.
105. Steinmetzer, T.; Sturzebecher, J. Progress in the development of synthetic thrombin inhibitors as new orally active anticoagulants. Curr. Med. Chem., 2004, 11, 2297-2321.
106. Salzet, M. Leech thrombin inhibitors. Curr. Pharm. Des., 2002, 8, 493-503.
107. McKeage, K.; Plosker, G.L. Argatroban, Drugs, 2001, 61, 515-522.
108. Petersen, P. Ximelagatran - a promising new drug in thromboembolic disorders. Curr. Pharm. Des., 2005, 11, 527-538.
109. Lee, W.M.; Larrey, D.; Olsson, R.; Lewis, J.H.; Keisu, M.; Auclert, L.; Sheth, S. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf., 2005, 28, 351-370.
110. Gould, W.R.; Leadley, R.J. Recent advances in the discovery and development of direct coagulation factor Xa inhibitors. Curr. Pharm. Des., 2003, 9, 2337-2347.
111. Jones, T.E.; Smith, B.J.; Polasek, J.F. Pharmacoeconomics of low-molecular-weight heparins: limitations of studies comparing them to unfractionated heparin. Expert Opin. Pharmacother., 2004, 5, 1887-1897.
112. Cheng, J.W. Fondaparinux: a new antithrombotic agent. Clin. Ther., 2002, 24, 1757-1769; discussion 1719.
113. Bajaj, M.S.; Birktoft, J.J.; Steer, S.A.; Bajaj, S.P. Structure and biology of tissue factor pathway inhibitor. Thromb. Haemost., 2001, 86, 959-972.
114. Vlasuk, G.P.; Rote, W.E. Inhibition of factor VIIa/tissue factor with nematode anticoagulant protein c2: from unique mechanism to a promising new clinical anticoagulant. Trends Cardiovasc. Med., 2002, 12, 325-331.
115. Kranjc, A.; Kikelj, D.; Peterlin-Masic, L. Recent advances in the discovery of tissue factor/factor VIIa inhibitors and dual inhibitors of factor VIIa/factor Xa. Curr. Pharm. Des., 2005, 11, 4207-4227.
116. Green, A.R.; Shuaib, A. Therapeutic strategies for the treatment of stroke. Drug Discov. Today, 2006, 11, 681-693.
117. Myohanen, H.; Vaheri, A. Regulation and interactions in the activation of cell-associated plasminogen. Cell Mol. Life Sci., 2004, 61, 2840-2858.
118. Behrendt N. The urokinase receptor (uPAR) and the uPAR-associated protein (uPARAP/Endol80): membrane proteins engaged in matrix turnover during tissue remodeling. Biol. Chem., 2004, 385, 103-136.
119. Jo, M.; Thomas, K.S.; Wu, L.; Gonias, S.L. Soluble urokinase-type plasminogen activator receptor inhibits cancer cell growth and invasion by direct urokinase-independent effects on cell signaling. J. Biol. Chem., 2003, 278, 46692-46698.
120. Blasi, F.; Carmeliet, P. uPAR: a versatile signalling orchestrator. Nat. Rev. Mol. Cell Blol., 2002, 3, 932-943.
121. Duffy, M.J. Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers. Biochem. Soc. Trans., 2002, 30, 207-210.
122. Andreasen, P.A.; Kjoller, L.; Christensen, L.; Duffy, M.J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer, 1997, 72, 1-22.
123. Borgono, C.A.; Diamandis, E.P. The emerging roles of human tissue kallikreins in cancer. Nat. Rev. Cancer, 2004, 4, 876-890.
124. Bhoola, K.D.; Misso, N.L.; Naran, A.; Thompson, P.J. Current status of tissue kallikrein inhibitors: importance in cancer. Curr. Opin. Investig. Drugs, 2007, 8, 462-468.
125. Denmeade, S.R.; Nagy, A.; Gao, J.; Lilja, H.; Schally, A.V.; Isaacs, J.T. Enzymatic activation of a doxortibicin-peptide prodrug by prostate-specific antigen. Cancer Res., 1998, 58, 2537-2540.
126. DiPaola, R.S.; Rinehart, J.; Nemunaitis, J.; Ebbinghaus, S.; Rubin, E.; Capanna, T.; Ciardella, M.; Doyle-Lindrud, S.; Goodwin, S.; Fontaine, M.; Adams, N.; Williams, A.; Schwartz, M.; Winchell, G.; Wickersham, K.; Deutsch, P.; Yao, S.L. Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer. J. Clin. Oncol., 2002, 20, 1874-1879.
127. DeFeo-Jones, D.; Brady, S.F.; Feng, D.M.; Wong, B.K.; Bolyar, T.; Haskell, K.; Kiefer, D.M.; Leander, K.; McAvoy, E.; Lumma, P.; Pawluczyk, J.M.; Wai, J.; Motzel, S.L.; Keenan, K.; Van Zwieten, M.; Lin, J.H.; Garsky, V.M.; Freidinger, R.; Oliff, A.; Jones, R.E. A prostate-spccific antigen (PSA)-activated vinblastine prodrug selectively kills PSA-secreting cells in vivo. Mol. Cancer Ther., 2002, 1, 451-459.
128. Denmeade, S.R.; Jakobsen, C.M.; Janssen, S.; Khan, S.R.; Garrett, E.S.; Lilja, H.; Christensen, S.B.; Isaacs, J.T. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J. Natl. Cancer Inst., 2003, 95, 990-1000.
129. Latham, J.P.; Searle, P.F.; Mautner, V.; James, N.D. Prostate-specific antigen promoter/erihancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res., 2000, 60, 334-341.
130. Eder, J.P.; Kantoff, P.W.; Roper, K.; Xu, GX; Bubley, G.J.; Boyden, J.; Gritz, L.; Mazzara, G.; Oh, W.K.; Arlen, P.; Tsang, K.Y.; Panicali, D.; Schlom, J.; Kufe, D.W. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin. Cancer Res., 2000, 6, 1632-1638.
131. Heiser, A.; Maurice, M.A.; Yancey, D.R.; Coleman, D.M.; Dahm, P.; Vieweg, J. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res., 2001, 61, 3388-3393.
132. Barrou, B.; Benoit, G.; Ouldkaci, M.; Cussenot, O.; Salcedo, M.; Agrawal, S.; Massicard, S.; Bercovici, N.; Ericson, M.L.; Thiounn, N. Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. Cancer Immunol. Immunother., 2004, 53, 453-460.
133. Payne, V.; Kam, P.C. Mast cell tryptase: a review of its physiology and clinical significance. Anaesthesia, 2004, 59, 695-703.
134. Bachelet, I.; Munitz, A.; Levi-Schaffer, F. Tryptase as an inflammatory marker in allergic disease and asthma. Expert Rev. Clin. Immunol., 2005, 1, 63-73.
135. Temkin, V.; Kantor, B.; Weg, V.; Hartman, M.L.; Levi-Schaffer, F. Tryptase activates the mitogen-activated protein kinase/activator protein-1 pathway in human peripheral blood eosinophils, causing cytokine production and release. J. Immunol., 2002, 169, 2662-2669.
136. Sommerhoff, C.P.; Schaschke, N. Mast cell tryptase beta as a target in allergic inflammation: an evolving story. Curr. Pharm. Des., 2007, 13, 313-332.
137. Mentlein, R.; Gallwitz, B.; Schmidt, W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-hke peptide-1 (7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem., 1993, 214, 829-835.
138. Kieffer, T.J.; McIntosh, C.H.; Pederson, R.A. Degradation of glucose-dependent insuhnotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology, 1995, 136, 3585-3596.
139. Ahren, B. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes Care, 2007, 30, 1344-1350.
140. Marguet, D.; Baggio, L.; Kobayashi, T.; Bernard, A.M.; Pierres, M.; Nielsen, P.F.; Ribel, U.; Watanabe, T.; Drucker, D.J.; Wagtmann, N. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. USA, 2000, 97, 6874-6879.
141. Deacon, C.F.; Ahren, B.; Hoist, JJ. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? Expert Opin. Investig. Drugs, 2004, 13, 1091-1102.
142. Erdos, E.G.; Skidgel, R.A. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J., 1989, 3, 145-151.
143. Plamboeck, A.; Holst, J.J.; Carr, R.D.; Deacon, C.F. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both involved in regulating the metabolic stability of glucagon-like peptide-1 in vivo. Adv. Exp. Med Biol., 2003, 524, 303-312.
144. Lee, M.; Fridman, R.; Mobashery, S. Extracellular proteases as targets for treatment of cancer metastases. Chem. Soc. Rev., 2004, 33, 401-409.
145. Reddy, V.Y.; Zhang, Q.Y.; Weiss, S.J. Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins B, L, and S, by human monocyte-derived macrophages. Proc. Natl. Acad. Sci. USA, 1995, 92, 3849-3853.
146. Sukhova, G.K.; Shi, G.P.; Simon, D.I.; Chapman, H.A.; Libby, P. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J. Clin. Invest., 1998, 102, 576-583.
147. Berquin, I.M.; Sloane, B.F. Cathepsin B expression in human tumors. Adv. Exp. Med. Biol., 1996, 389, 281-294.